ADMA Biologics to Report Third Quarter 2025 Financial Results on November 5, 2025

Core Viewpoint - ADMA Biologics, Inc. is set to report its third quarter 2025 financial results on November 5, 2025, and will host a conference call to discuss these results and company updates [1]. Company Overview - ADMA Biologics is a U.S.-based biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases [3]. - The company currently offers three FDA-approved plasma-derived biologics: ASCENIV™ for primary humoral immunodeficiency, BIVIGAM® for primary humoral immunodeficiency, and NABI-HB® for enhanced immunity against hepatitis B [3]. - ADMA is also developing SG-001, a pre-clinical hyperimmune globulin targeting S. pneumonia [3]. - The company operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, and has a subsidiary, ADMA BioCenters, which collects source plasma for its products [3]. - ADMA holds numerous U.S. and foreign patents related to its products and candidates [3].